Biotech is hard.
We all know the binary nature of success vs failure but rarely consider macro factors such as prescribing trends and other drug discovery products. Simply put, the boat has sailed on this class of drug. The new reports (NEJM) on medications with multiple MOA (eg Retatruide) has push the boat out even further and it is not coming back.
We know that weight loss improves the majority of IIH (bariatric surgery data). Therefore these drugs will be tried first (as they result in weight loss, clearance of fatty liver, cardiovascular improvements, decreased cancer risk etc etc) with the expectation of IIH improvements as well.
I just cant see that there is room for IXC any more.
Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-72
-
- There are more pages in this discussion • 153 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable